ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

“Honor Roll” Of Top Investigators Who Won’t Be Funded Because Of Cuts

March 8, 1985

Abstracts of ‘Most Newsworthy’ Papers

June 3, 1977

NCI To Slow New Center Development To Assure Funding For Existing Commitments, King Says

February 14, 1975

NCI Seeks Changes In CIS Funding Plan With Next Recompetition

April 24, 1987

President’s Cancer Panel Urges Greater Emphasis On Prevention.

September 21, 2007

Post Starts Series With Horror Stories On Drug Testing; DeVita Says They Are “Slanted, Distorted”

October 23, 1981